[Kidney disease: potential of anti-inflammatory approaches for drug therapy].
Hayashi
Kazumi
K
kazumi.hayashi@jp.astellas.com
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D002908:Chronic Disease; D048909:Diabetes Complications; D015195:Drug Design; D005921:Glomerulonephritis / Q000150:complications; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006973:Hypertension / Q000150:complications; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007249:Inflammation / Q000150:complications*; D007674:Kidney Diseases / Q000188:drug therapy* / Q000209:etiology*; D016328:NF-kappa B / Q000037:antagonists & inhibitors; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors; D012084:Renin-Angiotensin System / Q000502:physiology
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007166:Immunosuppressive Agents; D016328:NF-kappa B; D047492:Peroxisome Proliferator-Activated Receptors; D047428:Protein Kinase Inhibitors; D019707:Receptors, Chemokine